ArticleBMC public health2025
Population-based seroprevalence survey: post-pandemic COVID-19 vaccination, related factors, and geographic distribution of vaccine acceptability in Chile.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Perceived barriers to accessing vaccination plans in pregnant women in Chile: a qualitative analysis.Archives of public health = Archives belges de sante publique · 2026Article
- Routine immunization in older adults beyond COVID-19: a qualitative analysis of experiences, perceived barriers and facilitators, and recommendations for improvement.BMC geriatrics · 2026Article
- Geospatial disparities in post-pandemic SARS-CoV-2 vaccination: Evidence from Chile beyond the national success.PLOS global public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPrevention of infectious diseases is based on host protection, especially using vaccines. Several factors have been linked to the acceptance of vaccines in the population. Chile achieved high COVID-19 vaccination coverage early in the pandemic. The study aimed to determine the prevalence of antigens and antibodies, vaccination status, geographical distribution, and factors related to vaccine acceptability.
methodsIn two Chilean cities, the fourth round of a population-based seroprevalence cross-sectional survey was conducted in May 2024. 654 participants aged seven or older were recruited. After signing consent, participants were interviewed, blood samples were taken to identify antibodies against SARS-CoV-2 using ELISA, and antigens were assessed through a nasal swab rapid test. Territorial analysis of the vaccine dose distribution was carried out.
resultsAll participants tested negative for antigens and positive for antibodies against SARS-CoV-2, with an overall vaccination uptake rate of 98,5%. However, their vaccination status was heterogeneous. Territorial distribution showed a slight geographical clustering of vaccine doses in both cities. 52.7% had the basic scheme and/or boosters, 32.1% had the bivalent vaccine, and 13.7% had anti-Omicron. Self-report identification with a risk group was not associated with vaccine adherence. City, age, education, and comorbidities were associated with perceived and actual risk discrepancies.
conclusionsOverall, vaccine acceptance is high. However, the acceptance of the last two doses was below expectations and showed heterogeneous geographical distribution. Adulthood is the most important predictor of vaccine uptake. Participants underestimated their level of risk. Risk communication must be improved, especially for risk groups, to help them perceive themselves as beneficiaries of vaccination. Efforts should be made to disseminate information on vaccine safety and counter misinformation to increase knowledge about vaccines.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.